12 May 2022
\n \n \n \n\n \n \n10 May 2022
\n \n \n \nOxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.
\n \n\n \n \n29 April 2022
\n \n \n \nWe are delighted to announce that the MRC Brain Network Dynamics Unit has received Collaborative Award funding from Wellcome for a substantial multi-year research programme designed to advance the understanding of why dopamine-producing nerve cells are especially vulnerable in Parkinson\u2019s.
\n \n\n \n \n19 April 2022
\n \n \n \nThe only project of its kind anywhere that studies patients with all types of acute vascular events - including strokes, heart attacks, aneurysms - in order to develop better diagnostic tests and treatments celebrates its 20th anniversary this month.
\n \n\n \n \n28 March 2022
\n \n \n \nA new DPAG-led review paper, published in the journal Brain, has shown that a poorly understood region of the brain called the claustrum may play an important role in how we experience pain.
\n \n\n \n \n7 March 2022
\n \n \n \nThe \u00a33.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.
\n \n\n \n \n7 March 2022
\n \n \n \nResearchers from the University of Oxford have used data from UK Biobank participants to look at changes to the brain on average 4.5 months after mild SARS-CoV-2 infection.
\n \n\n \n \n19 January 2022
\n \n \n \nResearchers from Oxford\u2019s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don\u2019t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.
\n \n\n \n \n19 January 2022
\n \n \n \nAssociate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.
\n \n\n \n \n7 January 2022
\n \n \n \nHuman-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.
\n \n\n \n \n5 January 2022
\n \n \n \nA \u00a3210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.
\n \n\n \n \n17 December 2021
\n \n \n \nA proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.
\n \n\n \n \n13 December 2021
\n \n \n \nScientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.
\n \n\n \n \n8 December 2021
\n \n \n \nMany congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.
\n \n\n \n \n19 November 2021
\n \n \n \nIn May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.
\n \n\n \n \n11 November 2021
\n \n \n \n\n \n \n3 November 2021
\n \n \n \nMembers of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.
\n \n\n \n \n27 October 2021
\n \n \n \nThe University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.
\n \n\n \n \n27 October 2021
\n \n \n \nResearch reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.
\n \n\n \n \n26 October 2021
\n \n \n \nA major new $9 million project funded by the Aligning Science Across Parkinson\u2019s (ASAP) initiative will map the original circuits vulnerable to Parkinson\u2019s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.
\n \n\n \n \n